Therapy of autoimmune diseases: clinical trials and new biologics.
Successful clinical efficacy trials have been recently completed for a growing array of new biologics. Prospects are improving for rational therapeutic interventions that potently interrupt adaptive immune response pathways. By contrast, disappointing results with antigen-based therapeutics highlight the difficulties of achieving tolerance in the context of active autoimmunity. Combination immunotherapy is probably necessary to sequentially or simultaneously inhibit inflammation, uncouple innate immune pathways, interrupt or ablate the adaptive memory response and promote antigen-specific tolerance in a suitable immunological context.
Nepom
Gerald T
GT
Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington 98101-2795, USA. nepom@vmresearch.org
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007167:Immunotherapy; D009103:Multiple Sclerosis / Q000188:drug therapy; D010455:Peptides / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate